Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition ∗

Felicita Andreotti,Massimo Massetti,Gilles Montalescot

DOI: https://doi.org/10.1016/j.jacc.2023.12.003

IF: 24

2024-02-07

Journal of the American College of Cardiology

Abstract:Corresponding Author Download : Download high-res image (61KB) Download : Download full-size image

cardiac & cardiovascular systems

What problem does this paper attempt to address?

Factor Ⅺ-a promising anticoagulation target

Li Xu,Guofeng Ma,Wenxia Zhang,Kej Ying

DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2016.04.018

2016-01-01

Abstract:Thromboembolic disorders are widely found nowadays.A certain percentage of bleeding event will occur in available anticoagulation therapies,especially for warfarin,which requires ongoing dose adjustment by means of regular laboratory monitoring to prevent under or over anticoagulation.Is there an approach which could provide antithrombotic protection with reduced bleeding and be convenient is the point of researches.Factor Ⅺ deficiency patients tend to decrease morbidity in thrombotic diseases, moreover,several animal experiments have demonstrated that factor Ⅺ deficiency could reduce thrombotic rate with little effect on hemostasis.Recent clinical studies have confirmed the similar result.Inhibition of factor Ⅺ activity may be a promising antithrombotic target.
Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives

Ana-Maria Vlădăreanu,Adrian Roşca

DOI: https://doi.org/10.2478/rjim-2023-0034

2023-12-28

Abstract:Factor XI is a zymogen with an important role in the coagulation cascade. It is activated by FXII, thrombin and or it can be autoactivated. It has a prothrombotic effect after being activated by thrombin, but also through its antifibrinolytic action, stabilizing the formed clot. Hereditary deficiency of FXI causes haemophilia C - a disease manifested by an usually provoked, small to moderate mucosal bleeding. People with severe FXI deficiency have a low risk of thrombotic events. Conversely, increased FXI values have been found to be associated with increased risk of venous thromboembolism and ischemic stroke. Lowering serum FXI levels has become a treatment target for the prevention of thrombotic events. New pharmacological agents - FXI inhibitors - have been investigated in phase II clinical trials, with promising results in terms of efficacy and safety in the prevention of thrombotic events. FXI inhibitors are emerging as new anticoagulant agents with broad indication prospects beyond direct oral anticoagulants and vitamin K antagonists.
Pharmacological and clinical appraisal of factor XI inhibitor drugs

Giovanni Occhipinti,Claudio Laudani,Marco Spagnolo,Simone Finocchiaro,Placido Maria Mazzone,Denise Cristiana Faro,Maria Sara Mauro,Carla Rochira,Federica Agnello,Daniele Giacoppo,Nicola Ammirabile,Davide Landolina,Antonino Imbesi,Giuseppe Sangiorgio,Antonio Greco,Davide Capodanno

DOI: https://doi.org/10.1093/ehjcvp/pvae002

2024-01-09

European Heart Journal - Cardiovascular Pharmacotherapy

Abstract:Abstract The evolution of anticoagulation therapy, from vitamin K antagonists to the advent of direct oral anticoagulants (DOACs) almost two decades ago, marks significant progress. Despite improved safety demonstrated in pivotal trials and post-marketing observations, persistent concerns exist, particularly regarding bleeding risk and the absence of therapeutic indications in specific subgroups or clinical contexts. Factor XI (FXI) has recently emerged as a pivotal contributor to intraluminal thrombus formation and growth, playing a limited role in sealing vessel wall injuries. Inhibiting FXI presents an opportunity to decouple thrombosis from haemostasis, addressing concerns related to bleeding events while safeguarding against thromboembolic events. Notably, FXI inhibition holds promise for patients with end-stage renal disease or cancer, where clear indications for DOACs are currently lacking. Various compounds have undergone design, testing, and progression to phase 2 clinical trials, demonstrating a generally favourable safety and tolerability profile. However, validation through large-scale phase 3 trials with sufficient power to assess both safety and efficacy outcomes is needed. This review comprehensively examines FXI inhibitors, delving into individual classes, exploring their pharmacological properties, evaluating the latest evidence from randomized trials, and offering insights into future perspectives.

pharmacology & pharmacy,cardiac & cardiovascular systems
Factor XI: structure, function and therapeutic inhibition

Ahmed E. Ali,Richard C. Becker

DOI: https://doi.org/10.1007/s11239-024-02972-5

2024-04-17

Journal of Thrombosis and Thrombolysis

Abstract:Arterial and venous thromboembolism is a major medical concern that requires therapeutic anticoagulation in various medical fields to prevent its drastic consequences. Despite significant advances in anticoagulant therapy, thrombosis remains a leading cause of morbidity and mortality worldwide. Traditional anticoagulants like heparin and vitamin K antagonists (VKAs) have shown efficacy in preventing and treating thrombosis but come with an inherent risk of bleeding due to their non-specific inhibition of multiple coagulation factors. Subsequent direct oral anticoagulants (DOACs), targeting specific factors such as Xa or thrombin, demonstrated improved safety profiles compared to VKAs, yet bleeding remains a concern. Accordingly, research is focused on developing anticoagulants with improved safety profiles. A safer class of anticoagulants would have broad appeal. The intrinsic pathway of coagulation, involving factor XI (FXI), has attracted attention as a potential target for safer anticoagulants. Preclinical studies and epidemiological data indicate that FXI deficiency or inhibition protects against thrombosis with minimal bleeding. Current research involves evaluating various FXI-directed strategies, and phase 2 studies have shown promising results in orthopedic surgery, atrial fibrillation, end-stage renal disease (ESRD), myocardial infarction, and ischemic stroke. Several agents, such as antisense oligonucleotides, monoclonal antibodies, small synthetic molecules, natural peptides, and aptamers, have been developed to inhibit FXI at different stages, offering potentially safer alternatives to traditional anticoagulants. However, the optimal balance between preventing thrombosis and the risk of bleeding associated with FXI inhibitors requires validation through extensive phase 3 clinical trials using definite clinical endpoints. Several of such trials are currently underway or planned to define the role of FXI inhibitors in clinical practice and determine the most suitable FXI inhibitor for each specific indication. The current review highlights the rationale behind developing FXI inhibitors, presenting the most advanced agents in development, summarizing completed clinical trials, and discussing ongoing research efforts.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease

Ahmed E. Ali,Richard C. Becker

DOI: https://doi.org/10.1007/s11239-024-02985-0

2024-04-27

Journal of Thrombosis and Thrombolysis

Abstract:Anticoagulant therapy is a mainstay in the management of patients with cardiovascular disease and related conditions characterized by a heightened risk for thrombosis. Acute coronary syndrome, chronic coronary syndrome, ischemic stroke, and atrial fibrillation are the most common. In addition to their proclivity for thrombosis, each of these four conditions is also characterized by local and systemic inflammation, endothelial/endocardial injury and dysfunction, oxidative stress, impaired tissue-level reparative capabilities, and immune dysregulation that plays a critical role in linking molecular events, environmental triggers, and phenotypic expressions. Knowing that cardiovascular disease and thrombosis are complex and dynamic, can the scientific community identify a common pathway or specific point of interface susceptible to pharmacological inhibition or alteration that is likely to be safe and effective? The contact factors of coagulation may represent the proverbial "sweet spot" and are worthy of investigation. The following review provides a summary of the fundamental biochemistry of factor XI, its biological activity in thrombosis, inflammation, and angiogenesis, new targeting drugs, and a pragmatic approach to managing hemostatic requirements in clinical trials and possibly day-to-day patient care in the future.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Introduction to a review series on factor XI

Thomas L. Ortel

DOI: https://doi.org/10.1182/blood.2023020723

IF: 20.3

2024-04-12

Blood

Abstract:Factor XI is located near the "top" of the contact phase pathway, activated by factor XIIa to factor XIa, which then goes on to activate factor IX to factor IXa. Thrombin is also able to activate factor XI, thereby providing a feedback loop resulting in the amplification of thrombin generation. Deficiency of factor XI is associated with bleeding manifestations, but the clinical phenotype is variable and differs from the bleeding observed with deficiency of factor IX or factor VIII, also part of the contact phase pathway. Recently, it has been noted that inhibiting factor XIa provides an antithrombotic effect with a low risk of bleeding. This observation has led to an increase in interest in targeting factor XI and factor XIa as an alternative to the direct oral anticoagulants, targeting factor Xa and thrombin.

hematology
Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?

D. Santagata,M.P. Donadini,W. Ageno

DOI: https://doi.org/10.1016/j.blre.2023.101119

IF: 10.626

2023-08-12

Blood Reviews

Abstract:Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs effectively reduce the rates of thrombotic events, they simultaneously increase the risk of bleeding. Moreover, their risk-to-benefit balance is problematic in some patients, such as those with severe chronic kidney disease or those at high bleeding risk. A novel anticoagulation method, FXI inhibition has emerged as a promising alternative. It demonstrates a strong rationale for the prevention and treatment of venous thromboembolism and the potential fulfillment of unmet clinical needs in the cardiovascular field. A number of FXI inhibitors are currently undergoing clinical investigation. The objective of this review is to provide an overview of early results of research on FXI inhibitors in the cardiovascular setting, offering valuable insights into their potential role in shaping the future of anticoagulation.

hematology
The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials

Emma DeLoughery,Sven Olson,Cristina Puy,Owen McCarty,Joseph Shatzel,Emma P. DeLoughery,Sven R. Olson,Owen J. T. McCarty,Joseph J. Shatzel

DOI: https://doi.org/10.1055/s-0039-1692439

2019-06-19

Seminars in Thrombosis and Hemostasis

Abstract:Abstract Although anticoagulation without hemorrhage is a primary aim, this vision has remained as yet out of reach. Even despite the superior safety profile of the direct oral anticoagulants, hemorrhage remains a major risk of anticoagulation. Selective inhibition of the contact pathway of coagulation, specifically coagulation factor XI (FXI) and/or factor XII (FXII), has now substantial epidemiologic and preclinical data supporting the notion that these factors contribute to pathologic thrombosis and are yet primarily dispensable for in vivo hemostasis. In this way, targeting FXI and FXII may revolutionize the future anticoagulation landscape. Several drugs are under development for this purpose, including: ISIS 416858, a FXI antisense oligonucleotide which impairs hepatic synthesis of FXI; MAA868, a monoclonal antibody that binds the procoagulant enzymatic site of both zymogen and activated FXI (FXIa); BAY 1213790, a monoclonal antibody that binds the procoagulant enzymatic site of FXIa only; and AB023, a monoclonal antibody that inhibits activated FXII-mediated activation of FXI, along with two small molecules in clinical trials. Each of these drugs have demonstrated favorable safety profiles in their phases 1 and 2 studies to date, with preclinical data also supporting efficacy of abrogating thrombosis in various animal models. Other benefits of some of these drugs include once-monthly dosing and safety in patients with renal or hepatic impairment, while others offer quickly metabolized parenteral options, thus providing more convenient and widely available anticoagulation options. Though still far from the marketplace, drugs targeting FXI and FXII have the potential to usher in a new era of anticoagulation therapy.

peripheral vascular disease,hematology
Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors

Nûn K Bentounes,Sophie Melicine,Anne Céline Martin,David M Smadja,Nicolas Gendron

DOI: https://doi.org/10.1016/j.jdmv.2023.04.002

Abstract:Thrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs (i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors (i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use with favorable pharmacological profile and not requiring monitoring, particularly for venous thromboembolism treatment and prevention and stroke prevention in atrial fibrillation. However, despite having a better safety profile than VKA, their bleeding risk is not negligible. Therefore, research is underway to develop new anticoagulant therapies with a better safety profile. One of these news approaches to reduce the risk of bleeding is to target the coagulation in the intrinsic pathway, in particular the contact activation, with the ultimate goal of preventing thrombosis without impairing hemostasis. Based on epidemiological data with patients with inherited factor XI (FXI) deficiency and preclinical studies, FXI emerged as the most promising candidate target separating hemostasis from thrombosis. This review summaries the role of FXI and FXIa in hemostasis, provides evidence of initial success with FXI pathway inhibitors in clinical trials (such as IONIS-FXIRx, fesomersen, osocimab, abelacimab, milvexian, asundexian or xisomab 3G3) and highlights the opportunities and challenges for this next generation of anticoagulants.
Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances

Yunqing Xia,Yu Hu,Liang Tang

DOI: https://doi.org/10.3390/ph16060866

2023-06-11

Abstract:Background: While current clinically administered anticoagulant medications have demonstrated effectiveness, they have also precipitated significant risks: severe bleeding complications including, but not limited to, gastrointestinal hemorrhaging and intracranial and other life-threatening major bleedings. An ongoing effort is being made to identify the best targets for anticoagulant-targeted drugs. Coagulation factor XIa (FXIa) is emerging as an important target of current anticoagulant treatment. Objective: This review will summarize the development of anticoagulants and recent advances in clinical trials of experimental factor XI inhibitors from a clinical application perspective. Results: As of 1 January 2023, our search screening included 33 clinical trials. We summarized the research progress of FXIa inhibitors from seven clinical trials that evaluated their efficacy and safety. The results showed no statistically meaningful distinction in the primary efficacy between patients receiving FXIa inhibitors compared to controls (RR = 0.796; 95% CI: 0.606-1.046; I2 = 68%). The outcomes did not indicate a statistical difference in the occurrence of any bleeding between patients receiving FXIa inhibitors compared to controls (RR = 0.717; 95% CI: 0.502-1.023; I2 = 60%). A subgroup analysis found significant differences in severe bleeding and clinically relevant hemorrhaging in subjects receiving FXIa inhibitors compared to Enoxaparin (RR = 0.457; 95% CI: 0.256-0.816; I2 = 0%). Conclusions: Clinical trials to date have indicated that factor XIa is a potential anticoagulation target, and factor XIa inhibitors may play an important role in the development of anticoagulants.
Therapeutic Potential of FXI Inhibitors: Hype or Hope?

Mattia Galli,Giovanni Occhipinti,Luis Ortega-Paz,Francesco Franchi,Fabiana Rollini,Salvatore Brugaletta,Davide Capodanno,Sebastiano Sciarretta,Dominick J Angiolillo

DOI: https://doi.org/10.1007/s40265-024-02049-w

2024-07-30

Drugs

Abstract:Significant advancements have shaped the landscape of anticoagulant therapy in the past two decades, including the introduction of direct oral anticoagulants (DOACs), characterized by favorable safety and efficacy profiles and reduced drug-to-drug or food interaction resulting in excellent patient compliance. However, residual concerns still exist with standard-of-care anticoagulant therapy, including the inability to use DOACs in several clinical settings and the need to further reduce the risk of bleeding. Recent improvements in the understanding of the mechanisms behind thrombus formation have led to the awareness that the intrinsic pathway of the coagulation cascade may play an important role in pathological thrombosis, but not in hemostasis. This has represented the rationale for targeting this pathway with factor XI (FXI) inhibitors, with the aim of uncoupling hemostasis and thrombosis. Clinical evidence from patients with FXI deficiency further supports this concept. A number of compounds with different mechanisms of action have been developed to target FXI (i.e., asundexian, abelacimab, Ionis-FXIRx, milvexian, osocimab, and Xisomab 3G). To date, the majority of available trials have not gone beyond completion of phase 2 and results are conflictive making it difficult to appraise the clinical benefit of these compounds in the different clinical settings where they have been tested (i.e., atrial fibrillation, acute ischemic stroke, acute myocardial infarction, end-stage renal disease, total knee arthroplasty). Moreover, the largest phase 3 randomized trial designed to test the efficacy of asundexian over apixaban in patients with atrial fibrillation, the OCEANIC-AF, has been prematurely stopped as a result of the inferior efficacy of asundexian. In this review we discuss the pharmacological properties and available evidence generated thus far for factor XI inhibitors, providing a perspective on the current state of these drugs.

pharmacology & pharmacy,toxicology
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism

Tingting Li,Jiang Liu,Weihua Wu

DOI: https://doi.org/10.3389/fcvm.2022.975767

2022-10-31

Abstract:Venous thromboembolism (VTE) is a common cause of mortality and disability in hospitalized patients, and anticoagulation is an essential therapeutic option. Despite the increasing use of direct oral anticoagulants, complications and adverse drug reactions still occur in patients with VTE. Within 5 years, 20% of patients with VTE experience recurrence, and 50% of patients with deep vein thrombosis develop post-thrombotic syndrome. Furthermore, bleeding due to anticoagulants is a side effect that must be addressed. Therefore, safer and more effective anticoagulant strategies with higher patient compliance are urgently needed. Available epidemiological evidence and animal studies have shown that factor XI (FXI) inhibitors can reduce thrombus size and loosen the thrombus structure with a relatively low risk of bleeding, suggesting that FXI has an important role in thrombus stabilization and is a safer target for anticoagulation. Recent clinical trial data have also shown that FXI inhibitors are as effective as enoxaparin and apixaban in preventing VTE, but with a significantly lower incidence of bleeding. Furthermore, FXI inhibitors can be administered daily or monthly; therefore, the monitoring interval can be longer. Additionally, FXI inhibitors can prolong the activated partial thromboplastin time without affecting prothrombin time, which is an easy and common test used in clinical testing, providing a cost-effective monitoring routine for patients. Consequently, the inhibition of FXI may be an effective strategy for the prevention and treatment of VTE. Enormous progress has been made in the research strategies for FXI inhibitors, with abelacimab already in phase III clinical trials and most other inhibitors in phase I or II trials. In this review, we discuss the challenges of VTE therapy, briefly describe the structure and function of FXI, summarize the latest FXI/activated FXI (FXIa) inhibitor strategies, and summarize the latest developments in clinical trials of FXI/FXIa inhibitors.
Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings

Omri Cohen,Davide Santagata,Walter Ageno

DOI: https://doi.org/10.3324/haematol.2023.283682

2024-05-24

Haematologica

Abstract:Anticoagulants have long been fundamental in preventing and treating thromboembolic disorders, with a recent shift of focus towards direct oral anticoagulants, thanks to their ease of use, efficacy, and safety. Despite these advancements, bleeding complications remain a major concern with any anticoagulant, highlighting the need for safer drugs. Factor XI (FXI) inhibitors have emerged as promising agents in this regard, offering a novel approach by targeting upstream factors in the coagulation system. Phase 2 trials have shown encouraging outcomes, indicating a reduced bleeding risk compared to traditional anticoagulants, particularly in the context of cardiovascular disease management when combined with antiplatelet therapy. However, the variability in findings and limited efficacy data call for a cautious interpretation pending phase 3 trial insights. These trials are essential for validating the potential of FXI inhibitors to balance bleeding risk reduction and maintain anticoagulant efficacy. This review explores the pharmacology, potential indications, clinical data, and future directions of FXI inhibitors, providing a perspective on their evolving role in anticoagulant therapy. It also provides a detailed analysis of data from published clinical trials on FXI inhibitors in various indications. Preliminary data from ongoing trials is also outlined. As the field moves forward, a cautiously optimistic outlook can be expected, focusing on comprehensive data from phase 3 trials to define the role of FXI inhibitors in various clinical scenarios.

hematology
[New perspective of anticoagulation in intensive care unit: basic and clinical advances in coagulation factor XII and XI inhibitors]

Ruihua Wang,Zhiyun Yang,Shaolin Ma,Feng Zhu

DOI: https://doi.org/10.3760/cma.j.cn121430-20230917-00794

Abstract:Anticoagulation therapy stands as a key treatment for thrombotic diseases. The consequential bleeding risk tied to existing anticoagulation methods significantly impacts patient prognosis. In the intensive care unit (ICU), patients often necessitate organ support, leading to the inevitable placement of artificial devices in blood vessels, thereby requiring anticoagulation treatment to avert clot formation that might impede organ support. Nevertheless, these patients commonly encounter a heightened risk of bleeding. Hemophilia B, identified in 1953, manifests as a deficiency in coagulation factor XI (FXI), which focused people's perspective on the endogenous coagulation pathway, that is, the contact pathway. Upon interaction between the surface of artificial devices and FXII, FXII activates, subsequently triggering FXI and initiating the "coagulation cascade" within the contact pathway. Inhibitors targeting the contact pathway encompass two primary categories: FXII inhibitors and FXI inhibitors, capable of impeding this process. This article reviews the role of FXII and FXI in activating the contact pathway, seeking to illuminate their contributions to thrombus formation. By listing the relatively mature drugs and their indications, clinicians are familiar with this new anticoagulant.
catalytic domain Dominant factor XI deficiency caused by mutations in the factor XI

Hongli Wang,David Gailani,Dmitri V. Kravtsov,Wenman Wu,Joost C. M. Meijers,Mao-Fu Sun,Morey A. Blinder,Thao P. Dang

2004-01-01

Abstract:http://bloodjournal.hematologylibrary.org/content/104/1/128.full.html Updated information and services can be found at: (2497 articles) Hemostasis, Thrombosis, and Vascular Biology (1597 articles) Free Research Articles (3667 articles) Clinical Trials and Observations Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information about subscriptions and ASH membership may be found online at:
The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies

Ivan D Tarandovskiy,Mikhail V Ovanesov

DOI: https://doi.org/10.1016/j.thromres.2023.11.024

Abstract:Introduction: Growing evidence supports the importance of factor (F) XI activation for thrombosis and hemostasis as well as inflammation and complement systems. In this study, we evaluated the effect of activated FXI (FXIa) on the detection of factor deficiencies by global hemostasis assays of thrombin generation (TG), plasmin generation (PG), and clot formation and lysis (CFL). Materials and methods: An absorbance and fluorescence microplate assay was used to simultaneously observe TG, PG, and CFL in FV-, FVII-, FVIII-, and FIX-deficient plasmas supplemented with purified factors. Coagulation was initiated with tissue factor with or without FXIa in the presence of tissue plasminogen activator. Thrombin and plasmin peak heights (TPH and PPH), maximal clot density (MCD), times to clotting (CT), thrombin and plasmin peaks (TPT and PPT) and clot lysis (LyT) and a new parameter, clot lifetime (LiT), were evaluated. Results: TG/CFL were elevated by the FXIa at low FV (below 0.1 IU/mL), and at FVIII and FIX above 0.01 IU/mL. FXIa affected PG only at low FV and FVII. At high factor concentrations, FXIa reduced MCD. Thrombin and plasmin substrates had effect on CT, LyT, LiT and MCD parameters. Conclusions: FXIa reveals new relationships between TG, PG and CFL parameters in factor deficiencies suggesting potential benefits for discrimination of bleeding phenotypes.
Factor XI Inhibitors: perspectives in primary and secondary prevention of ischemic stroke

Canfora, Maria

DOI: https://doi.org/10.1007/s11739-024-03611-w

2024-05-15

Internal and Emergency Medicine

Abstract:Stroke is one of the most common causes of mortality and disability worldwide. Antithrombotic therapy represents the mainstay in primary and secondary prevention, both in cardioembolic and non-cardioembolic stroke. Particularly, direct oral anticoagulants play a crucial role in atrial fibrillation, the most common cause of cardioembolic stroke, whereas single or dual antiplatelet therapy is preferred in non-cardioembolic stroke. However, the limitations related to the residual risk of cardioembolic or cerebrovascular events, and the risk of major bleeding, still represent unmet medical needs. To overcome them, new drugs inhibiting Factor XI (FXI) and Factor XII have been proposed, with a selective inhibition of contact pathway of coagulation, delineating a new anticoagulant approach. This review provides a summary of the currently available evidence and future perspectives on FXI inhibitors, that can represent an additional therapeutic option in the primary and secondary prevention of cardioembolic and non-cardioembolic ischemic stroke, also in challenging therapeutic contexts.

medicine, general & internal
New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants

Ma’Lik D. Woodland,Anthony Thompson,Amanda Lipford,Navneet Goyal,John C. Schexnaildre,Madhusoodanan Mottamal,Daniel K. Afosah,Rami A. Al-Horani

DOI: https://doi.org/10.1021/acsomega.3c09335

IF: 4.1

2024-03-12

ACS Omega

Abstract:Factor XIIa (FXIIa) functions as a plasma serine protease within the contact activation pathway. Various animal models have indicated a substantial role for FXIIa in thromboembolic diseases. Interestingly, individuals and animals with FXII deficiency seem to maintain normal hemostasis. Consequently, inhibiting FXIIa could potentially offer a viable therapeutic approach for achieving effective and safer anticoagulation without the bleeding risks associated with the existing anticoagulants....

chemistry, multidisciplinary
Blood coagulation factor XII—a neglected player in stroke pathophysiology

Mirko Pham,Guido Stoll,Bernhard Nieswandt,Martin Bendszus,Christoph Kleinschnitz

DOI: https://doi.org/10.1007/s00109-011-0812-9

2011-09-10

Journal of Molecular Medicine

Abstract:Ischemic stroke is a devastating disease which, in most cases, is caused by thrombotic occlusion of brain arteries. The molecular mechanisms involved in microvascular thrombus formation during focal cerebral ischemia are not well understood. As a consequence, the current antithrombotic drugs used to treat acute stroke or prevent stroke recurrence either show limited efficacy or put patients at risk for serious bleeding complications. The serine protease blood coagulation factor XII (FXII) initiates the intrinsic pathway of coagulation which, together with the extrinsic pathway, culminates in the formation of fibrin. A physiological function of FXII in clot formation and hemostasis in vivo has been questioned for more than 50 years. This was mainly due to the fact that hereditary FXII deficiency does not induce any bleeding phenotype in humans. However, recent studies in transgenic mice challenged this concept by demonstrating that FXII deficiency prevents pathological thrombus formation, but does not affect regular hemostasis. These findings entailed investigations in relevant disease models of thromboembolism including ischemic stroke. The present review summarizes the pathophysiological role of FXII in experimental cerebral ischemia and highlights novel therapeutic strategies based on FXII inhibition.

genetics & heredity,medicine, research & experimental
The AZALEA-TIMI 71 Study and the Future of Factor XI Inhibition: Reflections from the American Heart Association Scientific Congress 2023

Karen Lipworth

DOI: https://doi.org/10.33590/emjcardiol/10304347

2024-01-25

EMJ Cardiology

Abstract:Since its earliest days, the effective use of anticoagulation for prevention of stroke and other thromboembolic events has been limited by the risk and fear of bleeding, which was long believed to be inevitable. However, new understanding of the coagulation cascade suggests that, by targeting factor XI, it may be possible to protect patients from pathological thrombosis without significantly affecting physiological haemostasis, and thus greatly reduce the risk of bleeding. The AZALEA-TIMI 71 trial is the first study to provide definitive evidence that factor XI inhibition substantially reduces bleeding compared to a standard-of-care direct oral anticoagulant (DOAC). Based on an interview with Principal Investigator Christian T. Ruff, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Boston, Massachusetts, USA, this article explains the significance of the AZALEA-TIMI 71 trial results, which showed an unprecedented reduction in the rate of bleeding with abelacimab, an investigational dual-acting factor XI/XIa inhibitor, compared with the DOAC rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition ∗

Factor Ⅺ-a promising anticoagulation target

Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives

Pharmacological and clinical appraisal of factor XI inhibitor drugs

Factor XI: structure, function and therapeutic inhibition

The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease

Introduction to a review series on factor XI

Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?

The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials

Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances

Therapeutic Potential of FXI Inhibitors: Hype or Hope?

Factor XI, a potential target for anticoagulation therapy for venous thromboembolism

Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings

[New perspective of anticoagulation in intensive care unit: basic and clinical advances in coagulation factor XII and XI inhibitors]

catalytic domain Dominant factor XI deficiency caused by mutations in the factor XI

The effect of factor XIa on thrombin and plasmin generation, clot formation, lysis and density in coagulation factors deficiencies

Factor XI Inhibitors: perspectives in primary and secondary prevention of ischemic stroke

New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants

Blood coagulation factor XII—a neglected player in stroke pathophysiology

The AZALEA-TIMI 71 Study and the Future of Factor XI Inhibition: Reflections from the American Heart Association Scientific Congress 2023